equillium
present
data
american
college
rheumatology
meeting
demonstrating
modulation
improves
kidney
skin
pathology
preclinical
models
systemic
lupus
erythematosus
studies
validate
ongoing
clinical
development
itolizumab
treatment
systemic
lupus
erythematosus
lupus
nephritis
la
jolla
globe
newswire
equillium
nasdaq
eq
clinical
stage
biotechnology
company
developing
novel
immune
modifying
therapies
severe
diseases
today
announced
data
presented
demonstrating
modulation
pathway
itolizumab
improves
kidney
skin
pathology
mouse
models
systemic
lupus
erythematosus
sle
data
presented
virtually
american
college
rheumatology
acr
virtual
convergence
november
posters
made
available
publications
section
equillium
website
et
saturday
november
studies
provide
insight
role
pathway
lupus
nephritis
specifically
pathogenesis
glomerulonephritis
wider
context
systemic
lupus
findings
establish
alcam
cells
cells
models
lupus
disease
importantly
work
highlights
role
pathway
plays
promoting
disease
creating
inflammatory
environment
recruits
cells
neutrophils
inflammatory
macrophages
ameliorated
blocking
chaim
putterman
professor
department
rheumatology
albert
einstein
college
medicine
stated
evidence
increased
signaling
kidneys
lupus
nephritis
patients
corresponding
efficacy
blockade
animal
models
support
therapeutic
potential
itolizumab
new
treatment
people
experiencing
lupus
nephritis
serious
manifestation
lupus
currently
treatments
approved
food
drug
pathway
plays
important
role
activity
trafficking
pathogenic
drive
autoimmune
disease
studies
underscore
therapeutic
potential
blocking
treat
multiple
lupus
pathologies
added
stephen
connelly
chief
scientific
officer
equillium
results
provide
validation
supportive
ongoing
clinical
trials
itolizumab
lupus
patients
believe
targeting
pathway
could
provide
therapeutic
benefit
posters
american
college
rheumatology
virtual
convergence
title
modulation
ameliorates
kidney
skin
disease
spontaneous
murine
lupus
model
abstract
id
first
author
samantha
chalmers
date
saturday
november
time
et
title
amelioration
immune
glomerulonephritis
via
modulation
abstract
id
author
samantha
chalmers
date
saturday
november
time
et
itolizumab
itolizumab
monoclonal
antibody
selectively
targets
pathway
pathway
plays
central
role
modulating
activity
trafficking
cells
drive
number
diseases
itoluzumab
currently
evaluated
multiple
clinical
trials
patients
severe
diseases
including
acute
disease
agvhd
lupus
nephritis
uncontrolled
asthma
equillium
acquired
rights
itolizumab
exclusive
partnership
biocon
limited
itolizumab
marketed
india
trade
name
alzumab
treatment
chronic
plaque
psoriasis
received
emergency
use
approval
india
treat
cytokine
release
syndrome
patients
moderate
severe
acute
respiratory
distress
syndrome
equillium
equillium
biotechnology
company
leveraging
deep
understanding
immunobiology
develop
novel
products
treat
severe
autoimmune
inflammatory
disorders
high
unmet
medical
need
equillium
developing
itolizumab
multiple
severe
diseases
including
agvhd
lupus
nephritis
uncontrolled
asthma
information
visit
forward
looking
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
statements
include
limited
statements
regarding
potential
benefit
treating
patients
lupus
nephritis
lupus
erythematosus
itolizumab
equillium
business
strategy
equillium
plans
expected
timing
developing
itolizumab
potential
benefits
itolizumab
potential
equillium
ongoing
planned
clinical
trials
show
safety
efficacy
risks
contribute
uncertain
nature
statements
include
potential
delays
commencement
enrollment
completion
clinical
trials
reporting
data
therefrom
risk
studies
completed
planned
uncertainties
related
equillium
capital
requirements
equillium
plans
product
development
including
initiation
restarting
completion
clinical
trials
reporting
data
therefrom
uncertainties
caused
recent
restarting
equip
equalise
clinical
trials
pause
whether
results
clinical
trials
validate
support
safety
efficacy
itolizumab
changes
competitive
landscape
use
cash
ways
timing
expected
impact
market
volatility
cash
reserves
risks
uncertainties
described
fully
caption
risk
factors
elsewhere
equillium
filings
reports
united
states
securities
exchange
commission
statements
contained
press
release
speak
date
made
equillium
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
investor
contact
christine
zedelmayer
chief
operating
officer
ir
media
contact
katherine
carlyle
smith
senior
account
associate
canale
communications
